Sight Sciences Q2 revenue $17.2M (+37% YoY); net loss $23.8M; FY22 guidance $68-72M

Sight Sciences, Inc.

2023-Q2 EPS reported -$0.99 revenue$32,111,000

Surgical Glaucoma revenue $15.9M (+33% YoY); Dry Eye revenue $1.3M (+143% YoY).
Gross margin expanded to 84% from 82% YoY on manufacturing cost reductions.
Operating expenses rose 75% to $37.4M, driven by personnel and R&D investment.
Cash and equivalents $220.1M; total debt $33.0M as of June 30, 2022.
Full-year 2022 revenue guidance: $68-72M, representing 39-47% growth over 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.